Immune-mediated adverse events associated with immune checkpoint inhibitors therapy

In recent years, immunotherapy is the main emphasis approach for malignant tumors treatment due to the development and registration of a new class of drugs -immune checkpoint inhibitors. Results of the randomized clinical trials, which showed a benefit in overall survival in comparison with standard therapy, was the basis for registration of this class of medicines [1-3]. Their toxicity profile is more favorable. However, the adverse reactions, which accrues during immunotherapy, are essentially new and different from standard chemotherapy. The standard management algorithm compensates the variety of immune-mediated adverse reactions [4]. Early detection and timely treatment is necessary for the successful management of these adverse reactions.